The Efficiency of Recombinant Alpha Eptacog in Haemostatis Management of Haemophilic Patients with Elective Arthroplasty

Abstract

Haemophilia is considered to be the most severe coagulopathy, characterized by a deficiency either of factor VIII (hemophilia A) or coagulation factor IX (hemophilia B), presenting various degrees of severity depending on the residual factor level. Haemarthrosis is the most common clinical expression of a haemophiliac patient. Its repetitive character will cause irreversible lesions in the joints, which mark the beginning of a chronic condition - haemophiliac arthropathy, which slowly develops throughout the patient�s life, leading eventually to ankylosis. Over time, these joints will require total prosthesis, in order to improve locomotor activity. Achieving effective hemostasis is an essential element for the possibility of performing this type of surgery, due to the increased risk of bleeding, of a vital nature, at this category of patients. A series of clinical trials have been carried out to research the role of the Eptacog Alpha Recombinant treatment in the reduction of bleeding in haemophiliac patients with present inhibitors, to whom total arthroplasty is carried out at the level of various joints. In this regard, this paper aims to highlight the effectiveness of Eptacog Alpha Recombinant in the management of haemostasis in haemophiliac patients, with indication of total endoprosthesis.